Alnylam Pharmaceuticals

Associate Medical Director, Global Safety Medical Review

Alnylam Pharmaceuticals  •  $193k - $261k/yr  •  United States (Remote)  •  3 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Overview

Alnylam is the industry leader in the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to address the unmet needs of patients with debilitating diseases. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality and is now advancing a robust pipeline of investigational RNAi therapeutic medicines. Please visit www.alnylam.com for more information.

The Associate Medical Safety Director role is responsible for performing medical case review and providing medical expertise across individual case safety assessment, with emphasis on maintaining a consistent and harmonized medical review approach. This role will support ongoing review of safety data and aggregate datasets to identify emerging trends, patterns, inconsistencies, and potential safety signals, and will provide medical and clinical input into data review plans, safety surveillance activities, and safety monitoring strategies. The Associate Medical Safety Director will interface across all levels and functional areas of SRM and partner closely with Clinical Development, Data Management, Pharmacovigilance, and other cross-functional teams. The role will also support medical device safety assessment, including review and evaluation of device-related safety information and potential safety concerns.

Summary of Key Responsibilities

  • Perform daily medical review and causality assessment of ICSRs in an accurate, consistent, and timely manner to contribute to the continuous signal detection and management process.
  • Support and participate in medical device safety assessments, including evaluation of MDR-related cases and determination of whether reported events meet applicable criteria for public health threats, regulatory reporting, escalation, or further medical assessment.
  • Collaborate with other pharmacovigilance colleagues to align a harmonized approach to identifying, evaluating, and communicating safety issues.
  • Identify topics for escalation and collaborate with Safety Product Leads to investigate potential safety signals.
  • Support and participate in the ongoing review of safety data and aggregate datasets to identify emerging trends, patterns, inconsistencies, and potential safety signals.
  • Provide medical and clinical input into data review plans, surveillance activities, and safety monitoring strategies, ensuring appropriate and consistent medical assessment of safety information.
  • Collaborate with SRM Quality and Case Management teams to identify case review issues and inconsistencies and work on addressing these issues under the leadership of the Head of Medical Review.
  • Participate in process improvements for the Medical Review team.
  • Maintain close communication with the case processing and medical case review vendors.

Qualifications

  • MD degree with a minimum of 1 year of clinical medical practice required.
  • Minimum of 3 years of pharmaceutical industry experience in a medical review or related pharmacovigilance role required.
  • Strong clinical acumen with broad knowledge and experience across multiple therapeutic areas.
  • Demonstrated ability to synthesize, critically evaluate, and interpret safety data from multiple sources, including individual case safety reports, aggregate safety data, and other relevant safety information.
  • Strong analytical, critical-thinking, and problem-solving skills, with the ability to assess complex medical and safety issues and identify areas requiring further investigation or escalation.
  • Excellent written and verbal communication skills, with the ability to effectively communicate medical and safety findings to cross-functional stakeholders.
  • Strong understanding of international pharmacovigilance regulations and drug safety requirements. Working knowledge of applicable FDA, EU, and ICH guidelines, regulations, and initiatives governing safety reporting and processing, particularly within the clinical trial environment, is highly preferred.
  • Knowledge of or experience in medical review of medical devices and/or combination-product safety information is preferred.
  • Ability to work effectively in a fast-paced, complex, and collaborative environment while managing multiple priorities and meeting rapidly approaching timelines.
  • Demonstrated ability to work collaboratively with cross-functional teams, case processing teams, medical review vendors, and other pharmacovigilance stakeholders to ensure high-quality, consistent, and timely safety assessments.

#LI-EW1 #LI-Remote

The pay range below reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on a number of factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus or sales incentive) and an annual long-term incentive award (e.g., equity).

Alnylam’s robust Total Rewards package is designed to support your overall health and well-being. We offer comprehensive benefits including medical, dental, and vision coverage, life and disability insurance, a lifestyle reimbursement program, flexible spending and health savings accounts and a 401(k)with a generous company match. Eligible employees enjoy paid time off, wellness days, holidays, and two company-wide recharge breaks. We also offer generous family resources and leave. Our commitment to your well-being reflects our belief that caring for our people fuels the impact we create together.

Learn more about these and additional benefits offered by Alnylam by visiting the Benefits section of the Careers website: https://www.alnylam.com/careers

U.S. Pay Range

$192,800—$260,800 USD

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

SILENCE DISEASE. AMPLIFY LIFE.™

Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.

Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.

We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024).

We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America.

See our social media community guidelines: https://bit.ly/2FcRhJy.

Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861

Fraudulent Recruitment Activity

Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

Industry
Biotech & Life Sciences
Company Size
1,001-5,000 employees
Headquarters
Cambridge, Massachusetts
Year Founded
2002
Social Media